FREELINE THERAPEUTICS HOLDIN (FRLN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:FRLN • US35655L2060

6.48 USD
0 (0%)
At close: Feb 16, 2024
6.48 USD
0 (0%)
After Hours: 2/16/2024, 8:00:24 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to FRLN. FRLN was compared to 525 industry peers in the Biotechnology industry. The financial health of FRLN is average, but there are quite some concerns on its profitability. FRLN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • FRLN had negative earnings in the past year.
  • In the past year FRLN has reported a negative cash flow from operations.
FRLN Yearly Net Income VS EBIT VS OCF VS FCFFRLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -50M -100M

1.2 Ratios

  • FRLN's Return On Assets of -101.44% is on the low side compared to the rest of the industry. FRLN is outperformed by 79.22% of its industry peers.
  • Looking at the Return On Equity, with a value of -166.21%, FRLN is doing worse than 70.44% of the companies in the same industry.
Industry RankSector Rank
ROA -101.44%
ROE -166.21%
ROIC N/A
ROA(3y)-79.36%
ROA(5y)-79.42%
ROE(3y)-108.32%
ROE(5y)-106.61%
ROIC(3y)N/A
ROIC(5y)N/A
FRLN Yearly ROA, ROE, ROICFRLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150

1.3 Margins

  • FRLN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRLN Yearly Profit, Operating, Gross MarginsFRLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for FRLN has been increased compared to 1 year ago.
  • There is no outstanding debt for FRLN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FRLN Yearly Shares OutstandingFRLN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 1M 2M 3M 4M
FRLN Yearly Total Debt VS Total AssetsFRLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -16.64, we must say that FRLN is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -16.64, FRLN is doing worse than 88.34% of the companies in the same industry.
  • FRLN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.64
ROIC/WACCN/A
WACCN/A
FRLN Yearly LT Debt VS Equity VS FCFFRLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

  • FRLN has a Current Ratio of 1.95. This is a normal value and indicates that FRLN is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of FRLN (1.95) is worse than 80.24% of its industry peers.
  • FRLN has a Quick Ratio of 1.95. This is a normal value and indicates that FRLN is financially healthy and should not expect problems in meeting its short term obligations.
  • FRLN's Quick ratio of 1.95 is on the low side compared to the rest of the industry. FRLN is outperformed by 78.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.95
FRLN Yearly Current Assets VS Current LiabilitesFRLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

  • FRLN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.48%.
EPS 1Y (TTM)-49.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • FRLN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.20% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.48%
EPS Next 2Y29.2%
EPS Next 3Y28.42%
EPS Next 5Y14.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FRLN Yearly Revenue VS EstimatesFRLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 2026 2027 2028 2029 2030 100M 200M 300M
FRLN Yearly EPS VS EstimatesFRLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • FRLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FRLN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FRLN Price Earnings VS Forward Price EarningsFRLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRLN Per share dataFRLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

  • A more expensive valuation may be justified as FRLN's earnings are expected to grow with 28.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.2%
EPS Next 3Y28.42%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for FRLN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FREELINE THERAPEUTICS HOLDIN / FRLN FAQ

Can you provide the ChartMill fundamental rating for FREELINE THERAPEUTICS HOLDIN?

ChartMill assigns a fundamental rating of 2 / 10 to FRLN.


Can you provide the valuation status for FREELINE THERAPEUTICS HOLDIN?

ChartMill assigns a valuation rating of 1 / 10 to FREELINE THERAPEUTICS HOLDIN (FRLN). This can be considered as Overvalued.


Can you provide the profitability details for FREELINE THERAPEUTICS HOLDIN?

FREELINE THERAPEUTICS HOLDIN (FRLN) has a profitability rating of 0 / 10.


What is the financial health of FREELINE THERAPEUTICS HOLDIN (FRLN) stock?

The financial health rating of FREELINE THERAPEUTICS HOLDIN (FRLN) is 5 / 10.